Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
521 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 193 increasing their positions, 196 reducing their positions, and 42 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 9 → 15 (+6)
45% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 42
3% more funds holding
Funds holding: 504 → 521 (+17)
3% more capital invested
Capital invested by funds: $29B → $30B (+$978M)
2% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 196
33% less call options, than puts
Call options by funds: $116M | Put options by funds: $172M
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$469M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$126M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$112M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$79.6M |
| 5 |
Two Sigma Investments
New York
|
-$76.6M |
ALXN Hedge Fund Activity: Q2 2014 in Review
521 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2014, worth a combined $30B — up 3.4% from $29B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new ALXN positions and 42 closed out — a net gain of 19 holders — while 193 added to existing stakes and 196 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $289M. The largest seller was Fidelity Investments, cutting an estimated $469M.
- 521 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2014, up from 504 in Q1 2014.
- Funds reported $30B of Alexion Pharmaceuticals stock for Q2 2014, up 3.4% quarter-over-quarter.
- 61 funds opened new Alexion Pharmaceuticals positions in Q2 2014 and 42 closed out, a net change of +19 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2014 was T. Rowe Price Associates, an estimated $289M added.
- The largest Alexion Pharmaceuticals seller in Q2 2014 was Fidelity Investments, an estimated $469M sold.
Based on aggregated 13F filings for Q2 2014.